SIRT2-IN-9
Modify Date: 2024-10-04 12:29:54
SIRT2-IN-9 structure
|
Common Name | SIRT2-IN-9 | ||
|---|---|---|---|---|
| CAS Number | 522650-91-5 | Molecular Weight | 438.57 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C21H22N6OS2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SIRT2-IN-9SIRT2-IN-9 (compound 12) is a selective inhibitor of SRIT2 with an IC50 value of 1.3 μM. SIRT2-IN-9 inhibits proliferative activity of MCF-7 breast cancer cells. SIRT2-IN-9 can be used for the research of cancer[1]. |
| Name | SIRT2-IN-9 |
|---|
| Description | SIRT2-IN-9 (compound 12) is a selective inhibitor of SRIT2 with an IC50 value of 1.3 μM. SIRT2-IN-9 inhibits proliferative activity of MCF-7 breast cancer cells. SIRT2-IN-9 can be used for the research of cancer[1]. |
|---|---|
| Related Catalog | |
| Target |
SIRT2:1.3 μM (IC50) SIRT1:＞300 μM (IC50) SIRT3:＞300 μM (IC50) |
| In Vitro | SIRT2-IN-9 (1-100 μM; 15 min) dose-dependently inhibits SRIT2 with an IC50 value of 1.3 μM, and inhibits SRIT1 and SRIT3 with IC50s ＞300 μM[1]. SIRT2-IN-9 (0-50 μM; 72 h) affects cell viability of MCF-7 cells[1]. SIRT2-IN-9 (0-50 μM; 6 h) affects acetylation of α-tubulin protein[1]. Cell Proliferation Assay[1] Cell Line: MCF-7 breast cancer cell line Concentration: 0-50 μM Incubation Time: 72 hours Result: Dose-dependently inhibited cell proliferation of MCF-7 breast cancer cells. Western Blot Analysis[1] Cell Line: MCF-7 breast cancer cell line Concentration: 6.25, 12.5, 25 and 50 μM Incubation Time: 6 hours Result: Dose-dependently increased acetylation of α-tubulin protein. |
| References |
| Molecular Formula | C21H22N6OS2 |
|---|---|
| Molecular Weight | 438.57 |
| Storage condition | -20°C |